Jesper Mosolff Mathiesen

2005: PhD, Molecular Pharmacology (Industrial PhD fellow, Erhvervsforsker)
2001: MSc, Pharmacy

Jul 2008 – present: Postdoctoral fellow, Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Denmark and Department of Molecular and Cellular Physiology, Stanford University Medical School, Stanford University, USA

Aug 2006 – Jun 2008: Receptor pharmacologist (Senior scientist), Project manager, Department of Molecular Pharmacology, Zealand Pharma A/S, Denmark.

Aug 2005 – Jul 2006: Research scientist, Department of Molecular Pharmacology, 7TM Pharma A/S, Denmark.

Nov 2004 – Jul 2006: Postdoctoral fellow, Department of Molecular Pharmacology, 7TM Pharma A/S, Denmark.

Nov 2003 – May 2004: Visiting graduate student at Stanford University in the Lab of Professor Brian Kobilka, Department of Molecular and Cellular Physiology, Stanford University, USA.

Aug 2001 – Jul 2004: PhD student under the Danish Industrial PhD Fellowship Programme, Department of Molecular Pharmacology, H. Lundbeck A/S, Stanford University, USA and Department of Medicinal Chemistry, Danish University of Pharmaceutical Sciences, Copenhagen, Denmark.

Feb 2000 – Jan 2001: MSc thesis student, H. Lundbeck A/S, Departments of Molecular Pharmacology and Molecular Genetics, H. Lundbeck A/S.

2008: Research grant from the Lundbeck Foundation
2008: Stanford University Medical School Postdoctoral Scholarship
2008: The Danish Medical Research Council Postdoctoral Fellowship
2004: EU 6th framework programme associate
2001: Danish Industrial PhD Fellowship

My research interests are primarily on the structure, function and molecular pharmacology of G protein coupled receptors (GPCRs) also known as 7TM receptors. I study the effects of different ligand classes on receptor activation and function, signal transduction and regulation as well as their down stream effects and potential therapeutic use. In particular, I focus on allosteric modulation, functionally selective ligands and differential regulation of GPCRs.

My current research project aims to identify and characterize allosteric ligands for the ß2 adrenergic receptor and to use such ligands to understand the molecular mechanisms behind allosteric modulation, receptor activation in general as well as requirements for rational drug design. The project is performed partly at Institute for Medicinal Chemistry at FARMA and partly at Stanford University School of Medicine in the laboratory of Professor Brian Kobilka.

Finally, I am developing efficient and cost-effective assays for GPCRs and their multiple signaling pathways.

Schroeder R, Merten N, Mathiesen JM, Martini L, Letunic AK, Krop F, Blaukat A,

Fang Y, Tran E, Ulven T, Drewke C, Whistler J, Pardo L, Gomeza J, Kostenis E. The C-terminal tail of CRTH2 is a key molecular determinant that constrains GalphaI- and downstream-signaling cascade activation. J Biol Chem, 284:1324-36 (2009)

Uller L, Mathiesen JM, Alenmyr L, Korsgren M, Ulven T, Hogberg T, Andersson G, Persson CG, Kostenis E. Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. Respir. Res. 8: 16 (2007)

Mathiesen JM and Ramirez MT. The Metabotropic Glutamate Receptor 4 is Internalized and Desensitized upon Protein Kinase C Activation. Br. J. Pharmacol. 148: 279-90 (2006)

Ulven T, Receveur JM, Grimstrup M, Rist O, Frimurer TM, Gerlach LO, Mathiesen JM, Kostenis E, Uller L, Hogberg T. Novel Selective Orally Active CRTH2 Antagonists for Allergic Inflammation Developed from in Silico Derived Hits. J Med Chem. 49: 6638-41 (2006)

Mathiesen JM, Christopoulos A, Ulven T, Royer JF, Campillo M, Heinemann A, Pardo L and Kostenis E. On the mechanism of interaction of potent, surmountable and insurmountable antagonists with human CRTH2 receptors. Mol Pharmacol 69: 1441-53 (2006)

Mathiesen JM, Ulven T, Martini L, Gerlach LO, Heinemann A and Kostenis E. Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. Mol Pharmacol 68: 393-402 (2005)

Ritzén A, Mathiesen JM and Thomsen C. Molecular Pharmacology and therapeutic prospects of Metabotropic Glutamate Receptor Allosteric modulators. Bas Clin Pharmacol Toxicol. 97: 202-13 (2005)

Mathiesen JM, Svendsen N, Bräuner-Osborne H, Thomsen C and Ramirez MT. Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br. J. Pharmacol. 138: 1026-30 (2003)

Mathiesen JM and Ramirez MT. Allosteric Modulators of Group III Metabotropic Glutamate Receptors as Novel Therapeutics. Chapter in "Allosteric Receptor Modulation in Drug Targeting", editor Bowery N. G., Taylor Francis Group, New York. (2006)